NovoCure Ltd Files 8-K with Corporate Details

TL;DR

NovoCure filed an 8-K on 10/15/24 with updated corporate info. Jersey-based.

AI Summary

NovoCure Limited filed an 8-K on October 15, 2024, reporting under Regulation FD and including financial statements and exhibits. The filing details the company's principal executive offices located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF, with a principal business phone number of +44 (0) 15 3475 6700. The report confirms the company's incorporation in Jersey and its IRS Employer Identification Number.

Why It Matters

This 8-K filing provides essential corporate and contact information for NovoCure Ltd, serving as a public record for investors and regulatory bodies.

Risk Assessment

Risk Level: low — This filing is routine and primarily contains corporate information rather than material financial or operational updates.

Key Numbers

• 001-37565 — SEC File Number (Identifies the company's filing history with the SEC.)
• 98-1057807 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• NovoCure Limited (company) — Registrant
• Jersey (company) — Jurisdiction of incorporation
• No. 4 The Forum, Grenville Street St. Helier Jersey JE2 4UF (company) — Address of Principal Executive Offices
• +44 (0) 15 3475 6700 (company) — Registrant's telephone number

FAQ

Filing Documents

• nvcr-20241015.htm (8-K) — 25KB
• lunarfdadecisionpr.htm (EX-99.1) — 28KB
• 0001645113-24-000030.txt ( ) — 183KB
• nvcr-20241015.xsd (EX-101.SCH) — 2KB
• nvcr-20241015_lab.xml (EX-101.LAB) — 21KB
• nvcr-20241015_pre.xml (EX-101.PRE) — 12KB
• nvcr-20241015_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 15, 2024, the Company issued a press release announcing that that the U.S. Food and Drug Administration (FDA) has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated October 15 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: October 15, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR